2009 Portfolio News
News from the portfolios of HBM BioVentures and HBM BioCapital
ChemoCentryx's Traficet-EN demonstrates effectiveness in Crohn's disease (32 KB)07.12.2009
- Nereus Pharmaceuticals presents positive study of randomized phase 2 clinical trial of Plinabulin (NPI-2358) in non-small cell lung cancer (16 KB)
23.11.2009
- Biovitrum - The creation of a new niche specialty pharmaceutical company focused on rare diseases - with strong cash flow generation and growth potential (216 KB)
05.11.2009
- Probiodrug closes series B financing round exceeding Euro 36 million (USD 54 million) (27 KB)
02.11.2009
- Nabriva Therapeutics raises Euro 15 million (USD 22 million) (30 KB)
28.10.2010
- Asthmatx receives FDA advisory panel recommendation for 'approvable with conditions' for bronchial thermoplasty with the Alair system for severe Asthma (28 KB)
28.10.2009
- PTC Therapeutics initiates phase 2 clinical trial of Ataluren (PTC124) in patients with Hemophilia (12 KB)
26.10.2011
- Lux Biosciences's potential of LUVENIQ (LX211) as first disease modifying treatment for sight-threatening non-infectious Uveitis highlighted at American Academy of Ophthalmology (70 KB)
26.10.2009
- Lux Biosciences completes $50 million series B financing (142 KB)
19.10.2009
- Paratek Pharmaceuticals signs worldwide license and commercialization agreement for PTK 0796, broad-spectrum oral and IV antibiotic in phase 3 (33 KB)
08.10.2009
- mtm laboratories extends series C financing round by EUR 7 million bringing total to EUR 39 million (USD 57 million) (20 KB)
05.10.2009
- Sloning closes growth financing round led by LBBW Venture (13 KB)
25.09.2009
News
M&A Report
Links
Subscribe To Our Newsletter
Search
© HBM Partners AG 18.05.2012